Association of plasma natriuretic peptide levels with metabolic risk factors in ambulatory individuals

被引:189
作者
Wang, Thomas J.
Larson, Martin G.
Keyes, Michelle J.
Levy, Daniel
Benjamin, Emelia J.
Vasan, Ramachandran S.
机构
[1] Massachusetts Gen Hosp, Cardiol Div, Dept Med, Boston, MA 02114 USA
[2] Harvard Univ, Sch Med, Boston, MA USA
[3] Boston Univ, Dept Math & Stat, Boston, MA 02215 USA
[4] Natl Heart Lung & Blood Inst, Bethesda, MD USA
[5] Boston Univ, Sch Med, Prevent Med Sect, Boston, MA 02118 USA
[6] Boston Univ, Sch Med, Cardiol Sect, Boston, MA 02118 USA
关键词
atrial natriuretic factor; epidemiology; natriuretic peptides; risk factors;
D O I
10.1161/CIRCULATIONAHA.106.655142
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background-Experimental studies suggest that the natriuretic peptides influence lipid and fatty acid metabolism. Although it has been shown that obese individuals have reduced natriuretic peptide levels, conflicting data exist on the relation of natriuretic peptide levels to other metabolic risk factors. Methods and Results-We examined the association of plasma levels of B-type natriuretic peptide and N-terminal pro-atrial natriuretic peptide with metabolic risk factors, the metabolic syndrome, and insulin resistance in 3333 Framingham study participants free of heart failure (mean age, 58 years; 54% women). Regression analyses were performed, with adjustment for clinical and echocardiographic variables. Plasma natriuretic peptide levels were inversely associated with all components of the metabolic syndrome except for elevated blood pressure. Adjusted natriuretic peptide levels were lower in persons with the metabolic syndrome compared with those without the metabolic syndrome: In men, B-type natriuretic peptide was 24% lower (P < 0.001) and N-terminal pro-atrial natriuretic peptide was 16% lower (P < 0.001); in women, B-type natriuretic peptide was 29% lower (P < 0.001) and N-terminal pro-atrial natriuretic peptide was 18% lower (P < 0.001). Individuals with insulin resistance, as indicated by an elevated homeostasis model assessment (HOMA-IR) index, had lower levels of B-type natriuretic peptide (P=0.009 in men, P < 0.001 in women) and N-terminal pro-atrial natriuretic peptide (P < 0.001 in men, P < 0.001 in women). Conclusions-Having several metabolic risk factors is associated with low circulating natriuretic peptide levels, even after adjustment for body mass index. These findings raise the possibility that reduced natriuretic peptide activity is a manifestation of the metabolic syndrome, which may have important clinical and pathophysiological implications.
引用
收藏
页码:1345 / 1353
页数:9
相关论文
共 49 条
[1]  
Balkau B, 1999, DIABETIC MED, V16, P442
[2]   INCREASED PLASMA ATRIAL NATRIURETIC FACTOR AND REDUCED PLASMA-RENIN IN PATIENTS WITH POORLY CONTROLLED DIABETES-MELLITUS [J].
BELL, GM ;
BERNSTEIN, RK ;
LARAGH, JH ;
ATLAS, SA ;
JAMES, GD ;
PECKER, MS ;
SEALEY, JE .
CLINICAL SCIENCE, 1989, 77 (02) :177-182
[3]   Insulin stimulates glucose transport via nitric oxide/cyclic GMP pathway in human vascular smooth muscle cells [J].
Bergandi, L ;
Silvagno, F ;
Russo, I ;
Riganti, C ;
Anfossi, G ;
Aldieri, E ;
Ghigo, D ;
Trovati, M ;
Bosia, A .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2003, 23 (12) :2215-2221
[4]   Lipid mobilization with physiological atrial natriuretic peptide concentrations in humans [J].
Birkenfeld, AL ;
Boschmann, M ;
Moro, C ;
Adams, F ;
Heusser, K ;
Franke, G ;
Berlan, M ;
Luft, FC ;
Lafontan, M ;
Jordan, J .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (06) :3622-3628
[5]   Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity - Studies in subjects with various degrees of glucose tolerance and insulin sensitivity [J].
Bonora, E ;
Saggiani, F ;
Targher, G ;
Zenere, MB ;
Alberiche, M ;
Monauni, T ;
Bonadonna, RC ;
Muggeo, M .
DIABETES CARE, 2000, 23 (01) :57-63
[6]  
BUCKLEY MG, 1993, J HUM HYPERTENS, V7, P245
[7]   Angiotensin II and the endocrine pancreas: effects on islet blood flow and insulin secretion in rats [J].
Carlsson, PO ;
Berne, C ;
Jansson, L .
DIABETOLOGIA, 1998, 41 (02) :127-133
[8]  
Chattington PD, 1998, DIABETIC MED, V15, P375, DOI 10.1002/(SICI)1096-9136(199805)15:5<375::AID-DIA585>3.0.CO
[9]  
2-N
[10]   Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [J].
Cleeman, JI ;
Grundy, SM ;
Becker, D ;
Clark, LT ;
Cooper, RS ;
Denke, MA ;
Howard, WJ ;
Hunninghake, DB ;
Illingworth, DR ;
Luepker, RV ;
McBride, P ;
McKenney, JM ;
Pasternak, RC ;
Stone, NJ ;
Van Horn, L ;
Brewer, HB ;
Ernst, ND ;
Gordon, D ;
Levy, D ;
Rifkind, B ;
Rossouw, JE ;
Savage, P ;
Haffner, SM ;
Orloff, DG ;
Proschan, MA ;
Schwartz, JS ;
Sempos, CT ;
Shero, ST ;
Murray, EZ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19) :2486-2497